Efficacy of Direct Renin Inhibitors in Slowing Down the Progression of Diabetic Kidney Disease: A Meta-Analysis

Hanieh Akbariromani, Rushna Haseeb, Sumreen Nazly, Sushmita Pandey, Venkata Anirudh Chunchu, Sandesh Dhakal, Mary Anne Claudine Avena, Neelum Ali

Abstract

Albuminuria is a risk factor for chronic kidney disease and cardiovascular events in diabetic people. The pathogenic processes in these circumstances have been documented to be significantly influenced by enhanced renin-angiotensin system activity. The current meta-analysis was carried out to assess the efficacy of direct renin inhibitors in preventing the progression of diabetic kidney disease. This meta-analysis was conducted as per the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). We searched the relevant medical literature through PubMed, Cochrane library and EMBASE. The primary efficacy outcome was a percentage change in urine albumin-creatinine ratio (UACR) (in mg/g) level. Other primary efficacy outcomes included remission from microalbuminuria to normal albuminuria and progression from microalbuminuria to macroalbuminuria. Four randomized control studies were identified and included in the current meta-analysis involving 9,609 participants. The use of direct renin inhibitors was superior in reducing mean UACR compared to angiotensin receptor blockers and angiotensin-converting enzyme inhibitors. The pooled mean difference in UACR between direct renin inhibitors and the control group was 9.42% (95% CI: -15.70 to -3.15; p-value=0.005). The odds of progression from microalbuminuria to normal albuminuria are 1.26 times higher in patients receiving direct renin inhibitors compared to patients in the control group (OR: 1.26, 95% CI: 1.08-1.46, p-value=0.002). The odds of remission from microalbuminuria to macroalbuminuria were 20% lower in patients receiving direct renin inhibitors compared to patients in the control group (OR: 0.80, 95% CI: 0.69-0.93, p-value=0.003). The use of aliskiren is associated with a significant reduction in UACR, increased remission from microalbuminuria to normal albuminuria and decreased progression from microalbuminuria to macroalbuminuria.

Introduction And Background

Diabetic kidney disease is one of the leading causes of end-stage renal disease (ESRD) in the United States [1] and western countries [2]. Diabetic kidney disease prevalence is 20% to 30% among patients with type 1 diabetes and type 2 diabetes [3]. However, an increased percentage of individuals with type 1 diabetes progressed to ESRD [3]. Diabetic kidney disease is characterized by a progressive decline in estimated glomerular filtration rate (eGFR) and persistent albuminuria. Glomerular hyperfiltration, early kidney disease (microalbuminuria: urine albumin-excretion ratio (UAE) > 300 mg/d), overt kidney disease (macroalbuminuria: UAE > 300 mg/d), and ESRD are the stages of disease that are common to both type 1 and type 2 diabetes [4].

One of the important strategies to prevent the progression of chronic kidney disease in people with diabetic kidney disease is the utilization of renin-angiotensin-aldosterone system (RAAS) inhibitors. Blockage of RAAS can be attained by aldosterone antagonists, angiotensin II receptor blockers, angiotensin-converting enzyme inhibitors and direct renin inhibitors [5]. Blockage of RAAS utilizing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers has been found to reduce proteinuria, thus slowing diabetic kidney disease progression and reducing cardiovascular mortality and morbidity [6]. Blockage of receptors using angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers alone is incomplete and associated with increased levels of renin and angiotensin that may lead to unsustained, incomplete and weak suppression of aldosterone, thus leading to blunt response [7].

The direct renin inhibitors now sold commercially are imarikiren and aliskiren. Aliskiren is responsible for increased renal vasodilation showing better blockages of RAAS compared to angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in healthy individuals [8]. These effects might be particularly noticeable in diabetics with activated RAAS systems. Direct renin inhibitors seem to provide more efficient
RAAS blockade by preventing the escape of aldosterone in combination with angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors therapy. The study conducted by Parving et al. found that aliskiren significantly reduced proteinuria when given with angiotensin II receptor blockers independent of its blood pressure-lowering effects [9]. In addition, the total number of serious adverse events and adverse events remained similar in both the placebo and aliskiren groups [9].

As far as our knowledge goes, this is the first meta-analysis that compared the efficacy of direct renin inhibitors alone or in combination with angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors therapy. During the last 20 years, the outlook for diabetes patients with diabetic kidney disease has improved, probably because of the early aggressive lowering of blood pressure and blocking of the renin-angiotensin-aldosterone system [10]. However, still, a large, unmet need is there to form strategies for the prevention of the progression of chronic kidney disease. Thus, the current meta-analysis was carried out to assess the efficacy of direct renin inhibitors in the prevention of the progression of diabetic kidney disease.

**Review**

**Methods**

This meta-analysis was conducted as per the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).

**Search Strategy**

We searched the relevant medical literature through PubMed, Cochrane library and EMBASE using the following keywords: diabetic kidney disease, diabetic nephropathy, direct renin inhibitors, progression, efficacy, and clinical trial in all languages without putting a restriction on the date of publication. We also reviewed the reference list of all the identified articles to locate further eligible studies. The search strategy described was used to search for relevant articles to determine which studies satisfy the inclusion criteria. Titles and abstracts were screened independently by two authors followed by a full-text screening of relevant articles.

**Eligibility Criteria**

We included all randomized control trials looking at individuals with diabetic kidney disease receiving direct renin inhibitors either alone or in combination with angiotensin receptor blockers or angiotensin-converting enzyme (ACE) inhibitors that provided data on any of the outcomes assessed in the current meta-analysis (urine albumin-creatinine rate, remission from microalbuminuria to normal albuminuria, progression from microalbuminuria to macroalbuminuria and all-cause mortality) relative to monotherapy with an angiotensin receptor blocker, an ACE inhibitor or placebo. Individuals with diabetic kidney disease (type 1 diabetes and type 2 diabetes) are defined by the presence of urine albumin-creatinine ratio (UACR) > 30 mg/g or UAER > 30 mg/d. We excluded studies carried out in non-diabetic kidney disease patients. We also excluded reviews, observational studies, case series, letters, editorials and commentaries from the current meta-analysis.

**Assessment of Risk of Bias**

Two reviewers assessed the risk of bias independently of all included studies by using the checklist of the Cochrane Database of Systematic Reviews. The checklist assessed the risk of bias using six domains that included sequence generation, allocation concealment, attrition, blinding, selection bias and other reporting biases. The classification in each category was unclear, yes or no. Discrepancies between two reviewers were resolved by consensus or involvement of the third reviewer. RevMan software (version 5.4.1; Cochrane, London, United Kingdom) was used to draw the risk of bias graph.

**Outcomes Measures**

The primary efficacy outcome was a percentage change in UACR (in mg/g) level. The percentage changes of values were computed by subtracting the mean of the endpoints from the baseline mean and dividing it by the baseline value. The standard deviation calculation method was adopted from Cochrane Handbook version 5.1.1. Original data were collected in the form of mean and standard deviation. Articles in which median and interquartile ranges were reported and mean and standard deviation were calculated manually using values of the median, interquartile ranges and sample size were collected. Other primary efficacy outcomes included remission from microalbuminuria to normal albuminuria and progression from microalbuminuria to macroalbuminuria. Microalbuminuria is UACR=50-500 mg/g, and macroalbuminuria is UACR >300 mg/g. Secondary efficacy outcomes included changes in estimated glomerular filtration rate in milliliters per minute (mL/min).

**Data Extraction**
Data were extracted by two reviewers independently using custom-made data extraction forms on Microsoft Excel (Microsoft, Washington, United States). Data extracted included first author name, year of publication, intervention, sample size, follow-up period and outcomes. The original data were not modified, and calculations were carried out from the available data for the current meta-analysis.

**Data Synthesis**

For data analysis, RevMan software (version 5.4.1) was used. For binary outcomes, risk ratios along with 95% confidence intervals were calculated using Mantel-Haenszel random effect model. For continuous variables, mean differences and their 95% confidence interval were calculated. I² value was used to assess heterogeneity between study results, and the Cochrane Q test (significance set at 0.01) was used for statistical testing of heterogeneity. We were able to assess publication bias because of a limited number of studies.

**Results**

Figure 1 shows the PRISMA flowchart for the selection of studies. Overall, 124 articles were identified through online database searching. After removing duplicates, 116 articles were eligible for the title and abstract screening. Out of 116 articles, a full-text screening of 10 articles was carried out. Among all these studies, four randomized control studies were identified and included in the current meta-analysis involving 9,609 participants. Table 1 shows the characteristics of the included studies and participants.

![PRISMA flowchart of selection of studies](image)

**FIGURE 1: PRISMA flowchart of selection of studies**

PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
| Author name | Year | Setting | Intervention | Dose | Sample size | Follow-up | Mean age* | Male (%) | Mean baseline estimated GFR (ml/min)* |
|-------------|------|---------|--------------|------|-------------|-----------|-----------|---------|-------------------------------------|
| Ito et al. [11] | 2019 | Multicenter | Imarikiren | 5, 20, 40 and 80 mg/day | 277 | 14 weeks | 61 (10) | 219 (79.06) | 80 (19) |
| ARB | 70 | 62 (9) | 56 (80) | 83 (23) |
| Parving et al. [9] | 2008 | Multicenter | Aliskiren+ARB | 150 mg/day | 301 | 24 weeks | 59.9 (9.6) | 206 (68.4) | 66.5 (25.7) |
| ARB | 298 | 61.8 (9.6) | 221 (74.2) | 66.8 (24.5) |
| Parving et al. [12] | 2012 | Multicenter | Aliskiren+ARB/ACEI | 300 mg/day | 4,274 | 78 weeks | 64.6 (9.6) | 2,881 (67.4) | 57.0 (21.9) |
| ARB/ACEI | 4,287 | 64.4 (9.9) | 2,945 (68.7) | 57.0 (23.0) |
| Uzu et al. [13] | 2016 | Multicenter | Aliskiren | 150 mg/day | 49 | 24 weeks | 64.3 (10.2) | 36 (73.0) | 79.2 (24.3) |
| ARB | 53 | 63.3 (8.0) | 37 (70.0) | 73.9 (2.1) |

**TABLE 1: Characteristics of the included studies**

*Mean (standard deviation). GFR: glomerular filtration rate; ARB: angiotensin receptor blocker; ACEI: angiotensin-converting enzyme inhibitors.

Of all the included studies, two compared the monotherapy of direct renin inhibitors with angiotensin receptor blocker (ARB) [11,13], while two studies compared the combination of direct renin inhibitors with monotherapy of ARB or angiotensin-converting enzyme inhibitor (ACEI) [9,12]. The dose for ARB, ACEI and direct renin inhibitors varied in the included study. However, all included randomized controlled trials (RCTs) were designed to reach the maximum dose for direct renin inhibitors. The duration of the study ranged from 14 weeks to 78 weeks. Participants were mostly male and relatively older.

**Assessment of Risk of Bias**

The overall risk of bias was moderate. All four studies discussed the methods used for the generation of the randomization sequences and details related to allocation concealment. Three studies reported blinding of participants and investigators, and one RCT was open-label. All efficacy outcomes were based on the laboratory data; this will less likely affect these outcomes. The withdrawal rate of all studies was less than 20%. Figure 2 shows the risk of bias assessment graph.
Primary Efficacy Outcomes

Three out of four included studies assessed the impact of direct renin inhibitors on UACR involving overall 9,262 patients with type 2 diabetes. The use of direct renin inhibitors was superior in reducing mean UACR. The pooled mean difference in UACR was -9.42% (95% CI: -15.70 to -3.15; p-value=0.003). There was a significant heterogeneity (p-value<0.001) as shown in Figure 3.

Two out of four studies assessed the impact of direct renin inhibitors on remission from microalbuminuria to normal albuminuria including a total of 8,904 patients. Among patients who received direct renin inhibitors, 10% of patients progressed from microalbuminuria to normal albuminuria compared to 7.89% of patients in the control group. The odds of progression from microalbuminuria to normal albuminuria are 1.26 times higher in patients receiving direct renin inhibitors compared to the control group (OR: 1.26, 95% CI: 1.08-1.46, p-value=0.002). No significant heterogeneity was found among the study results (p-value=0.67) as shown in Figure 4.
Two out of four studies assessed the impact of direct renin inhibitors on progression from microalbuminuria to macroalbuminuria including a total of 8,904 patients with diabetic kidney disease. The odds of macroalbuminuria are 20% lower in patients receiving direct renin inhibitors compared to patients in the control group (OR: 0.80, 95% CI: 0.69-0.93, p-value=0.003). Heterogeneity was insignificant among the study results (p-value=0.70) as shown in Figure 5.

**FIGURE 5: Forest plot on the impact of direct renin inhibitors on progression from microalbuminuria to macroalbuminuria**

Sources: References [11-12]. df: degree of freedom, M-H: Mantel-Haenszel method.

**Secondary Efficacy Outcomes**

Two out of four studies assessed the impact of direct renin inhibitors on eGFR including overall 9,160 patients with type 2 diabetes. The direct renin inhibitor was not better than the control group in reducing eGFR in diabetes patients. The pooled mean difference in eGFR was -0.65 (95% CI: -2.12 to 0.82, p=0.39) as shown in Figure 6.

**FIGURE 6: Forest plot on the impact of direct renin inhibitors on GFR**

Sources: References [9,12]. GFR: glomerular filtration rate; df: degree of freedom.

**Safety Outcome**

Three studies assessed all-cause mortality including 9,507 patients with type 2 diabetes. No significant differences were reported in all-cause mortality between the two groups (OR: 0.93, 95% CI: 0.39-2.24, p-value=0.87) as shown in Figure 7.

**FIGURE 7: Forest plot on the impact of direct renin inhibitors on all-cause mortality**

Sources: References [9,11-12]. df: degree of freedom, M-H: Mantel-Haenszel method.

**Sensitivity Analysis**

A sensitivity analysis was performed by comparing the results of direct renin inhibitors as monotherapy with a combination of direct renin inhibitors and ACEI or ARB. Table 2 shows the results of the sensitivity analysis.
There is a significant reduction of UACR in combination therapy as compared to ARB alone. However, when direct renin inhibitors were given alone, an increase in percentage change in UACR was observed. In addition, when direct renin inhibitors were given in combination with ARB or ACEI, the odds of remission from microalbuminuria to normal albuminuria are significantly higher compared to ARB or ACEI only. However, monotherapy of direct renin inhibitors did not significantly improve remission. On the other hand, progression from microalbuminuria to macroalbuminuria is significantly lower in patients who received the combination of drugs.

| Outcomes                              | Direct renin inhibitors |
|---------------------------------------|------------------------|
|                                       | Monotherapy            | Combination            |
| UACR                                  | 7.50 (0.02, 14.98)*    | -14.97 (-20.85, -9.09)* |
| Remission from microalbuminuria to normal albuminuria | 1.07 (0.51-2.26)     | 1.27 (1.09-1.47)*     |
| Progression from microalbuminuria to macroalbuminuria | 0.50 (0.04-5.61)     | 0.80 (0.69-0.93)*     |

**TABLE 2: Results of sensitivity analysis**

*Significant at p-value<0.05. All values are presented as OR (95% CI) except UACR that is presented as mean percentage change with 95% CI. Combination therapy: direct renin inhibitor+angiotensin receptor blockers or angiotensin-converting-enzyme inhibitors. UACR: urine albumin-creatinine ratio.

**Discussion**

It is well recognized that one of the most effective therapeutic approaches for lowering the risk of cardiovascular and renal events in diabetic patients is to treat microalbuminuria by blocking the renin-angiotensin-aldosterone pathway [13]. In the present meta-analysis, direct renin inhibitor was associated with a significant reduction in UACR and also improvement in other outcomes including remission from microalbuminuria to normal albuminuria and progression from microalbuminuria to macroalbuminuria. To date, no published meta-analysis and systematic review have been conducted to evaluate the efficacy of direct renin inhibitors as monotherapy or in combination with ARB and ACEI.

Since the hazard of end-stage kidney disease is reported to be associated with albuminuria in past observational studies [14-15], a decrease in albuminuria is usually linked to a reduced risk of end-stage kidney disease. However, previous findings suggested that albuminuria might be a poor surrogate. It means that a decrease in the level of albuminuria often translates into long-term renoprotection could be wrong [16]. There has been much debate on whether albuminuria is a reliable surrogate for other outcomes. The effectiveness of direct renin inhibitors to enhance remission from microalbuminuria to normal albuminuria is evident in the current meta-analysis. However, in the current meta-analysis, combination therapy of aliskiren with either ARB or ACEI was found to be better in controlling the level of albuminuria. The enhancement in remission rates is notable considering that normalization of albuminuria has been associated with enhanced cardiovascular and renal outcomes in diabetic kidney patients [17].

Aliskiren is an efficient antihypertensive agent, and when it is added to either an ARB or ACEI, the enhanced surrogate markers for outcomes in certain studies are not specific and seem to suggest additional benefits that have not been demonstrated. For instance, it reduced urinary albumin excretion in diabetic kidney disease patients [18]. In this case, the findings of the Aliskiren in the Evaluation of Proteinuria in Diabetes trial, which compared aliskiren with placebo in patients with diabetic renal impairment who were also receiving losartan medication, are very significant [8]. In one study, patients who achieved a 50% decrease in UACR had a 59% lower adjusted hazard for kidney and cardiovascular events as compared to those individuals without a 50% reduction [19].

Regarding the safety of direct renin inhibitors, no significant difference was reported in terms of all-cause mortality. However, a past meta-analysis conducted on patients with nondiabetic kidney disease has raised issues on adverse events. The meta-analysis showed that combination therapy of direct renin inhibitors was associated with an increased risk of moderate hyperkalemia [20]. Prior studies had established the higher risks of hypotension and hyperkalemia associated with the combination of an ACE inhibitor and an ARB [21-22]. The randomized control trial conducted by Parving et al. reported more severe outcomes in patients receiving combination therapy of aliskiren and ARB [9]. Major adverse events that were significantly higher in the direct renin inhibitor group were hyperkalemia and hypotension. However, studies conducted by Ito et al. [11] and Parving et al. [9] did not show any significant difference between the two groups in terms of adverse events. Considering the benefits of direct renin inhibitors in terms of reducing UACR and albuminuria levels, further studies need to be continued in people with diabetic kidney disease. More surrogate markers of disease progression should be studied to give the best possible treatment to these
patients.

Currently, sodium/glucose cotransporter-2 inhibitors (SGLT2i) and finerenone combination therapy are beneficial options in slowing down the progression of diabetic kidney disease. However, direct renin inhibitors can also be used in combination with ARB/ACEI. Future trials and analyses will shed further light on this to determine the benefits and harms of both of these treatment options. The current meta-analysis has certain limitations. Firstly, we were able to include only four randomized control trials as most of the studies were conducted on nondiabetic kidney disease. Due to the limitations of studies, publication bias was also not assessed. Many of these included studies were small, resulting in few adverse safety events, and no significant differences were reported between the groups. That is why we did not compare serious adverse events between the two groups. Studies need to be conducted in the future to assess all measures of renal disease, especially in a high-risk population such as patients with diabetes.

Conclusions

The use of aliskiren is associated with a significant reduction in UACR, increased remission from microalbuminuria to normal albuminuria and decreased progression from microalbuminuria to macroalbuminuria. It is also evident in the current meta-analysis that combination therapy of direct renin inhibitors and ARB is more effective in decreasing the progression of kidney disease among patients with diabetes. Further research to clarify the role and safety of using aliskiren in combination therapy on important clinical outcomes is needed.

Additional Information

Disclosures

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Saran R, Robinson B, Abbott KC, et al.: US Renal Data System 2016 Annual Data Report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2017, 69:AT-8. 10.1053/j.ajkd.2016.12.004
2. Kramer A, Pippia S, Stel VS, et al.: Renal replacement therapy in Europe: a summary of the 2013 ERA-EDTA Registry Annual Report with a focus on diabetes mellitus. Clin Kidney J 2016, 9:457-69. 10.1093/ckj/sfv151
3. de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J: Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA. 2011, 305:2532-9. 10.1001/jama.2011.861
4. Mogensen CE: Microalbuminuria in prediction and prevention of diabetic nephropathy in insulin-dependent diabetes mellitus patients. J Diabetes Complicat. 1995, 9:337-49. 10.1016/1056-8727(95)80036-E
5. de Zeeuw D, Franchini G, Parving HH, et al.: Alumminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation. 2004, 110:921-7. 10.1161/01.CIR.0000139860.33974.28
6. Strippoli GF, Bonifati C, Craig ME, Navaneethan SD, Craig IC: Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev. 2006, CD006257. 10.1002/14651858.CD006257
7. Schjoedt KI, Andersen S, Rossing P, Tarnow L, Parving HH: Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia. 2004, 47:1956-9. 10.1007/s00125-004-1542-0
8. Fisher ND, Jan Danser AH, Nusssberger J, Dole WP, Hohlenberg N: Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation. 2008, 117:5199-205. 10.1161/CIRCULATIONAHA.108.767202
9. Parving HH, Persson F, Lewis JB, Lewis EJ, Hohlenberg NK: Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008, 358:2435-46. 10.1056/NEJMoa0708379
10. Brenner BM, Cooper ME, de Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001, 345:851-9. 10.1056/NEJMoa011161
11. Ito S, Kagawa T, Saiki T, Shimizu K, Kuroda S, Sano Y, Umeda Y: Efficacy and safety of iramikiren in patients with type 2 diabetes and microalbuminuria: a randomized, controlled trial. Clin J Am Soc Nephrol. 2019, 14:534-63. 10.2215/CJN.07720618
12. Parving HH, Brenner BM, McMurray JJ, et al.: Cardiovascular end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012, 367:2204-13. 10.1056/NEJMoa1208799
13. Uza T, Araki SI, Kashiwagi A, et al.: Comparative effects of direct renin inhibitor and angiotensin receptor blocker on albuminuria in hypertensive patients with type 2 diabetes. A randomized controlled trial. PLoS One. 2016, 11:e0164956. 10.1371/journal.pone.0164956
14. Ninomiya T, Perkovic V, de Galian BE, et al.: Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol. 2009, 20:1813-21. 10.1681/ASN.2008121270
15. Roscioni SS, Lambers Heerspink HJ, de Zeeuw D: Microalbuminuria: target for renoprotective therapy PRO.
16. Lambers Heerspink HJ, Gansevoort RT: Albuminuria is an appropriate therapeutic target in patients with CKD: the Pro view. Clin J Am Soc Nephrol. 2015, 10:1079-88.

17. Ruggenenti P, Fusi A, Ilieva AP, et al.: Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial. J Hypertens. 2011, 29:207-16.

18. Miao Y, Dohre D, Heerspink HJ, et al.: Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. Diabetologia. 2011, 54:44-50.

19. Araki S, Haneda M, Koya D, et al.: Reduction in microalbuminuria as an integrated indicator for renal and cardiovascular risk reduction in patients with type 2 diabetes. Diabetes. 2007, 56:1727-30.

20. Harel Z, Gilbert C, Wald R, et al.: The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis. BMJ. 2012, 344:e42.

21. Pfeffer MA, McMurray JJ, Velazquez EJ, et al.: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003, 349:1893-906.

22. Yusuf S, Teo KK, Pogue J, et al.: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008, 358:1547-59.